Historical Valuation
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Mersana Therapeutics Inc (MRSN) has a current Price-to-Book (P/B) ratio of NaN. Compared to its 3-year average P/B ratio of 22.90 , the current P/B ratio is approximately NaN% higher. Relative to its 5-year average P/B ratio of 15.44, the current P/B ratio is about NaN% higher. Mersana Therapeutics Inc (MRSN) has a Forward Free Cash Flow (FCF) yield of approximately NaN%. Compared to its 3-year average FCF yield of -84.02%, the current FCF yield is approximately NaN% lower. Relative to its 5-year average FCF yield of -57.50% , the current FCF yield is about NaN% lower.
P/B
Median3y
22.90
Median5y
15.44
FCF Yield
Median3y
-84.02
Median5y
-57.50
Competitors Valuation Multiple
AI Analysis for MRSN
The average P/S ratio for MRSN competitors is 20.52, providing a benchmark for relative valuation. Mersana Therapeutics Inc Corp (MRSN.O) exhibits a P/S ratio of 9.65, which is -52.99% above the industry average. Given its robust revenue growth of -12.61%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MRSN
1Y
3Y
5Y
Market capitalization of MRSN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MRSN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MRSN currently overvalued or undervalued?
Mersana Therapeutics Inc (MRSN) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -3.21. The fair price of Mersana Therapeutics Inc (MRSN) is between to according to relative valuation methord.
What is Mersana Therapeutics Inc (MRSN) fair value?
MRSN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Mersana Therapeutics Inc (MRSN) is between to according to relative valuation methord.
How does MRSN's valuation metrics compare to the industry average?
The average P/S ratio for MRSN's competitors is 20.52, providing a benchmark for relative valuation. Mersana Therapeutics Inc Corp (MRSN) exhibits a P/S ratio of 9.65, which is -52.99% above the industry average. Given its robust revenue growth of -12.61%, this premium appears unsustainable.
What is the current P/B ratio for Mersana Therapeutics Inc (MRSN) as of Jan 10 2026?
As of Jan 10 2026, Mersana Therapeutics Inc (MRSN) has a P/B ratio of NaN. This indicates that the market values MRSN at NaN times its book value.
What is the current FCF Yield for Mersana Therapeutics Inc (MRSN) as of Jan 10 2026?
As of Jan 10 2026, Mersana Therapeutics Inc (MRSN) has a FCF Yield of NaN%. This means that for every dollar of Mersana Therapeutics Inc’s market capitalization, the company generates NaN cents in free cash flow.
What is the current Forward P/E ratio for Mersana Therapeutics Inc (MRSN) as of Jan 10 2026?
As of Jan 10 2026, Mersana Therapeutics Inc (MRSN) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Mersana Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Mersana Therapeutics Inc (MRSN) as of Jan 10 2026?
As of Jan 10 2026, Mersana Therapeutics Inc (MRSN) has a Forward P/S ratio of NaN. This means the market is valuing MRSN at $NaN for every dollar of expected revenue over the next 12 months.